Copyright
©2005 Baishideng Publishing Group Inc.
World J Gastroenterol. Apr 28, 2005; 11(16): 2526-2529
Published online Apr 28, 2005. doi: 10.3748/wjg.v11.i16.2526
Published online Apr 28, 2005. doi: 10.3748/wjg.v11.i16.2526
Drugs | Dose (mg/m2 body surface/d) | Route of administration | Days of use |
Cisplatin | 20 | IV drip | Days 1-4 |
Doxorubicin | 40 | IV injection | Day 1 |
5-FU | 400 | IV drip | Days 1-4 |
α-INF1 | 5 MU/m2 body surface/d | S.C. injection | Days 1-4 |
Group A (n = 8) | Group B (n = 18) | |
Gender (male:female) | 7:1 | 16:2 |
Age (yr) | 46±9 | 45±10 |
HBsAg (positive:negative) | 7:1 | 17:1 |
Liver function (grade A:B) | 7:1 | 14:4 |
AFP (>500 mg/L:<500 mg/L) | 6:2 | 12:6 |
Primarily-treated: Recurrent | 2:6 | 10:8 |
Tumor staging (III:IVa:IVb) | 0:5:3 | 1:11:6 |
- Citation: Yin XY, Lü MD, Liang LJ, Lai JM, Li DM, Kuang M. Systemic chemo-immunotherapy for advanced-stage hepatocellular carcinoma. World J Gastroenterol 2005; 11(16): 2526-2529
- URL: https://www.wjgnet.com/1007-9327/full/v11/i16/2526.htm
- DOI: https://dx.doi.org/10.3748/wjg.v11.i16.2526